Objectives: Vancomycin-resistant enterococci (VRE) may colonize haemodialysis patients, but their epidemiology in this population is not well defined. Within the few last years, VRE strains have emerged and are increasingly isolated in the nosocomial environment in Greece, but colonization of dialysis patients has never been evaluated before. This study sought to determine the epidemiology of VRE colonization within this high-risk population and define the risk factors.
Introduction
Enterococcal strains with acquired resistance to vancomycin (vancomycin-resistant enterococci, VRE) were first described in 1986 and, since then, they have been encountered with increasing frequency in many countries. 1, 2 It has been shown that the incidence of VRE intestinal colonization or infection depends upon geographical parameters.
In the United States, infections and nosocomial outbreaks due to multiresistant VRE constitute a particularly serious problem, but colonization in the community is rarely, if ever, reported. The emergence and dissemination of VRE in the USA have been associated with a large consumption of vancomycin and other antimicrobials and lack of implementation of appropriate infection control practices.
1,2 A different situation prevails in Europe. VRE carriage in the community and VRE isolation from the food chain occur frequently in countries where antimicrobials like avoparcin have been used in animal husbandry, but VRE hospital outbreaks occur infrequently and serious infections are not common. 1 In Greece, the first VRE isolate was reported in 1999, 3 and within 2 years a polyclonal nosocomial dissemination of multiresistant vanA Enterococcus faecium strains was described. 4 Recently, an ICU outbreak due to a vanA Enterococcus faecalis 6 Thus, in contrast to other European countries, there has been a relatively late emergence of VRE followed by a rapid dissemination, while the occurrence of community carriage has never been assessed.
Several risk factors have been identified for VRE colonization or infection including chronic haemodialysis treatment. 2 In the USA, 32.7% of dialysis units report at least one colonized or infected patient. 7 VRE-colonized haemodialysis patients are not only more likely to develop a VRE infection, 8 but also demonstrate decreased survival. 9 It is important, therefore, to elucidate their mode of VRE acquisition and define colonization risk factors, but only a few studies have examined this high-risk population. 8 -13 As VRE strains are emerging in Greece, we investigated for the first time their possible detection among haemodialysis patients. We searched for VRE colonization among outpatients treated in four independent dialysis units located in the same district of Athens and referring their patients to the same local hospital. Isolates were characterized phenotypically and genotypically, they were typed by pulsed-field gel electrophoresis (PFGE) and clinical and demographic data were recorded to define colonization risk factors.
Materials and methods
During a 4 month period (September to December 2001), 334 non-replicate swab specimens were obtained from consecutive haemodialysis patients consenting to participate in the study. They were treated at four dialysis units (Units I to IV) located in west Athens. More than 90% of haemodialysis patients of this district are treated at these units. Unit I is located within the major local hospital, a 700-bed tertiary care public hospital; the others represent private centres. Most patients start therapy in this hospital and are also referred for admission there.
Units I to IV participated with 60, 67, 60 and 147 patients, respectively, representing 61.2% of their total number of patients. There were 180 males and 154 females with a mean age of 63.33 ± 14.12 years and a mean time on haemodialysis of 37.80 ± 41.20 months. Previous antimicrobial treatment (vancomycin or other antimicrobials except for teicoplanin) and hospital admission (equal to one or more admissions) within 6 months were recorded.
Swab specimens were obtained from stools or by rectal insertion. Specimens were inoculated on Enterococcosel agar (BBL, Becton Dickinson, Sparks, MD, USA) with 6 mg/L vancomycin (Elli-Lily, Athens, Greece) and incubated aerobically at 378C for 24 h.
14 Negative cultures were incubated for 48 h. Genus, species identification and susceptibility testing were carried out using the VITEK (GPI and GPS101 cards) and the ATB systems (bioMérieux, Marcy l'É toile, France). Susceptibilities to ampicillin, erythromycin, ciprofloxacin, vancomycin, teicoplanin, gentamicin (MIC > _ 512 mg/L) and streptomycin (MIC > _ 1024 mg/L) were interpreted according to NCCLS criteria. 15 Resistance to glycopeptides was confirmed by Etest (AB Biodisk, Solna, Sweden).
A multiplex PCR confirmed species identification of E. faecalis, E. faecium, Enterococcus gallinarum and Enterococcus casseliflavus and detected the major glycopeptide resistance genes (vanA, vanB, vanC 1 and vanC 2,3 ). 16 DNA fingerprinting was carried out using PFGE. 17 Band patterns were compared visually and with GelCompar software (Applied Maths, Kortrijk, Belgium). Patterns assigned to the same type differed by four or fewer bands, suggesting that the corresponding isolates could be epidemiologically related. 18 Statistical analysis was carried out with t-tests, and x 2 and Fisher exact tests using the SPSS software package.
This study was considered by the hospital scientific committee as adhering to ethical standards and was therefore approved.
Results
Enterococcus species were isolated from 60 patients. By multiplex PCR, 31 (51.7%) and 16 (26.7%) isolates were E. gallinarum and E. casseliflavus, respectively, whilst 13 (21.7%) were E. faecium. All 13 E. faecium strains possessed the vanA gene and were resistant to vancomycin and teicoplanin by the Etest. Hence, the frequency of VRE colonization was 3.9% (13 out of 334 patients).
Seven of the 13 VRE strains were isolated from patients treated in Unit IV (seven out of 147, 4.8%) and two originated from each of the other three units (Unit I: two out of 60, 3.3%; Unit II: two out of 67, 3.0%; and Unit III: two out of 60, 3.3%). All were resistant to ampicillin, erythromycin, ciprofloxacin and streptomycin and three were also resistant to gentamicin.
DNA fingerprinting allocated the 13 VRE isolates into seven distinct PFGE types designated A to G (Figure 1 ). Type B was the predominant type being represented by six isolates (46.2%), type A was represented by two isolates (15.4%), while there was one isolate each of types C to G (7.7% each). Two isolates of distinct types were obtained from Unit I (one type E, one type F), Unit II (one type B, one type D) and Unit III (one type B, one type G), while seven isolates representing three types originated from Unit IV (two type A, four type B and one type C).
The characteristics of VRE-colonized and non-colonized patients are depicted in Table 1 . VRE-positive patients were more likely to be males (92.3% versus 55.5%, P = 0.019, OR 9.64), to have been hospitalized during the last 6 months (61.5% versus 18.1%, P = 0.001, OR 7.255) and to have received any antimicrobial treatment during this period (69.2% versus 34.9%, P = 0.026, OR 4.199).
Because of the association between male sex and VRE colonization, a statistical analysis was undertaken to evaluate possible differences between all male and female patients. The only difference detected was that men were on haemodialysis treatment for a shorter period than women (32.9 ± 36.5 versus 45.05 ± 46.76 months, P = 0.01).
Discussion
In this study, 13 (3.9%) of 334 patients treated at four dialysis units were VRE carriers. Colonization prevalence ranged from 3.0% to 4.8% among units. All VRE strains were multiresistant vanA E. faecium and formed seven PFGE clusters. The most predominant type, B, was represented by six strains and was isolated from three units. In addition, six patients treated in a single unit shared two distinct genetic VRE types: two type A and four type B.
VRE colonization rates among haemodialysis patients have been evaluated before. [8] [9] [10] [11] [12] High frequencies ranging from 8.1% to 9.5% were demonstrated in three studies from the USA, 8, 9, 11 while lower numbers were reported by Tokars et al. 10 examining patients from seven unrelated units in Maryland and Virginia. In this study, VRE colonization prevalence was 5.8% ranging from 1.0% to 7.9% among units. Clustering was demonstrated in one unit, where among eight VRE isolates, three and two strains, respectively, belonged to distinct genetic types.
Only one European study searched for VRE colonization among haemodialysis patients in Belgium, a country where community carriage is known to occur. 1 Patients from 29 units were examined and colonized patients were identified in all except for two, while colonization rates ranged from 5.6% to 23.4%. 12 These high rates were partly attributed to the applied methodology, broth enrichment and prolonged incubation time, which increases isolation yields compared with direct plating. Molecular typing of isolates revealed a high genetic variability pointing to their community origin rather than spread among patients.
Finally, a prospective study from Tennessee demonstrated that haemodialysis patients admitted to a hospital with very high VRE isolation rates acquired a VRE strain from an epidemiologically linked patient colonized with an identical genotype. 13 This first report from Greece demonstrates a low prevalence of VRE-positive patients (3.9%), consistent with the recent emergence of VRE in this country. Our results strongly indicate that VRE transmission occurred between patients treated at independent units. This evidence of interfacility transmission points to a common source of acquisition, most probably a health care setting visited by all patients. Although the location of previous hospitalizations was not recorded to conclusively prove our hypothesis, this could only be the local hospital, to which patients are referred. VRE strains have been isolated in this hospital, but they were not available for typing. Finally, and similar to the findings of Tokars et al., 10 sharing of two distinct genetic types occurred among patients of a single unit raising concerns about intrafacility VRE transmission.
The analysis of putative risk factors for VRE colonization demonstrated that male gender (P = 0.019), prior hospitalization (P = 0.001) and prior antimicrobial treatment (P = 0.026) were significant factors. VRE colonization has already been linked to prior hospitalization among dialysis patients, [8] [9] [10] most probably reflecting VRE acquisition within the hospital and/or being related to the multitude of risk factors operating within this environment. A positive association between VRE colonization of patients and previous antimicrobial administration is established.
1,2 Among dialysis patients, the receipt of vancomycin only, or other antimicrobials only, or any antimicrobial during a time period ranging from 90 days to 2 years were significant risk factors for VRE colonization. [9] [10] [11] A predominance of male sex among colonized patients has never been reported before, and it remains to be shown whether it reflects some other significant association not assessed in our study, such as, for example, the impact of disease severity. 10 In conclusion, haemodialysis patients in Greece are colonized with VRE strains at a low frequency and there is strong evidence of interfacility transmission of strains. Our findings supplement previous observations from Greece demonstrating that multiresistant VRE isolates are rapidly spreading within the health care environment. The importance of restricting the use of antimicrobials and adhering strictly to appropriate infection control practices cannot be overemphasized. Further, prospective studies for a more precise elucidation of VRE acquisition modes and definition of risk factors within this high-risk population are in progress. 
